Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)
出版年份 2016 全文链接
标题
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)
作者
关键词
-
出版物
ChemMedChem
Volume 11, Issue 14, Pages 1517-1530
出版商
Wiley
发表日期
2016-06-17
DOI
10.1002/cmdc.201600148
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Drugging PI3K in cancer: refining targets and therapeutic strategies
- (2015) Timothy A Yap et al. CURRENT OPINION IN PHARMACOLOGY
- Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ
- (2015) John R. Somoza et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Molecules in medicine mini-review: isoforms of PI3K in biology and disease
- (2015) Bart Vanhaesebroeck et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Targeting PI3 kinase in cancer
- (2015) Todd M. Bauer et al. PHARMACOLOGY & THERAPEUTICS
- A beta version of life: p110β takes center stage
- (2015) Oncotarget
- Idelalisib: First Global Approval
- (2014) Anthony Markham DRUGS
- Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease
- (2014) Timothy D. Cushing et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring
- (2014) Martin Andrs et al. JOURNAL OF MEDICINAL CHEMISTRY
- Challenges in the clinical development of PI3K inhibitors
- (2013) Cristian Massacesi et al. Annals of the New York Academy of Sciences
- Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
- (2013) Xiaobei Zhang et al. CURRENT CANCER DRUG TARGETS
- Phosphoinositide 3-kinase α inhibitors: a patent review
- (2013) William A Denny EXPERT OPINION ON THERAPEUTIC PATENTS
- Enhanced PI3K p110 Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110 -Selective PI3K Inhibitor
- (2013) S. W. Brady et al. MOLECULAR CANCER THERAPEUTICS
- BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
- (2013) Ningshu Liu et al. MOLECULAR CANCER THERAPEUTICS
- Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer
- (2013) L-Y Huw et al. Oncogenesis
- Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
- (2012) M. Mao et al. CLINICAL CANCER RESEARCH
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches
- (2011) Giovanni Ligresti et al. CELL CYCLE
- Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors
- (2010) K. A. Edgar et al. CANCER RESEARCH
- PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling
- (2010) E. Halilovic et al. CANCER RESEARCH
- The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors
- (2010) Alex Berndt et al. Nature Chemical Biology
- Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non-Small Cell Lung Cancer Harboring K-RAS Mutations
- (2009) G. Konstantinidou et al. CANCER RESEARCH
- Targeting the PI3K signaling pathway in cancer
- (2009) Kwok-Kin Wong et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- The PTEN–PI3K pathway: of feedbacks and cross-talks
- (2008) A Carracedo et al. ONCOGENE
- PTEN-deficient cancers depend on PIK3CB
- (2008) S. Wee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search